We previously developed effective and useful immuno-adjuvants that activate effector cells. 9, 10 We constructed new anti-tumor drugs by altering the structure of a mycoplasma lipopeptide, MALP2, which is the basic component of immuno-adjuvants. MALP2, a natural tolllike receptor 2 (TLR2) ligand, consists of a mycoplasma peptide containing 13 amino acids and an N-terminal cysteine conjugated to 2 palmitate moieties (S-2,3-bis(palmitoyloxy)-propyl-cysteine [Pam2Cys/P2C]). 11, 12 Although natural lipopeptides/TLR2 ligands harbor some peptide sequence motifs that are necessary for biosynthetic processes, 13, 14 these are unnecessary if we generate the lipopeptides by chemical synthesis. However, synthetic lipopeptides must meet essential conditions for TLR2/TLR6 ligand activity 15, 16 (a small amino acid at the 2nd position 17 and a highly hydrophilic peptide sequence). 18, 19 Therefore, to increase anti-tumor immuno-adjuvant activity, we exchanged bacterial peptides for other functional peptide sequences that meet the conditions essential for TLR ligand activity. In a previous report, we named this process of designing and developing synthetic adjuvants "adjuvant engineering." [24] [25] [26] [27] [28] or TLR ligands conjugated with antigen peptide 29, 30 are widely used as vaccines.
Another study shows that gram-negative bacteria, such as Salmonella species, expressing identified tumor antigens are useful for tumor immunotherapy. 31 Thus, mimicking bacterial cells/materials may induce strong immune responses to antigens present on the original cells/materials.
Here, we developed cationic lipopeptides that bound electrostatically to negatively charged tumor cell membranes and used them to prepare tumor cells coated with lipopeptides/TLR2 ligands acting as immuno-adjuvants. We then examined the effects of these bacteriamimicking tumor cells (BMTC) as vaccines to initiate anti-tumor immune responses.
| MATERIALS AND METHODS

| Mice, cells and reagents
Wild-type and Tlr2 À/À C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan) and Oriental BioService (Kyoto, Japan), respectively. OT-I mice were kindly provided by Dr Hiroshi Kosaka (Osaka University). Mice were maintained under specific pathogen-free conditions in the animal facility of Osaka International Cancer Institute. 
| In vitro assays
Bone marrow-derived DC and splenocytes were stimulated with lipopeptides as previously described. 
| In vivo and ex vivo mouse models
The in vivo experiments with EG7-OVA and mWT1-C1498 cells were performed as previously described. P2CSK11 and P2CSK4, respectively) ( Figure 4B ). Next, we examined the effects of vaccines that did not contain free lipopeptides (P2CSK4; Figure 4C , left panel; and P2CSR11; Figure 4C , right panel). BMTC prepared with P2CSK4, but not those prepared with P2CSR11, showed less anti-tumor activity after free peptide was removed; this is because P2CSK4 binds tumor cell membranes more weakly than P2CSR11 ( Figure 4C ). Furthermore, we examined the cytotoxic activity of lipopeptides against different tumor cells using splenocytes from treated mice. P2CSR11 induced slightly higher levels of specific CTL activity, but lower levels of NK activity, than the other lipopeptides ( Figure 4D ). 40 We showed that anti-PD-L1 antibody increased the anti-tumor effects of BMTC coated with P2CSR11 ( Figure 5D ).
| DISCUSSION
Here, we showed that 2 novel synthetic lipopeptides adjuvants Although some researchers have investigated suitable peptide sequences that may confer TLR2 ligand activity on lipopeptides, [41] [42] [43] we succeeded in providing additional specific functions. 9, 10 Indeed, it is possible to incorporate several functions by connecting different functional peptides in tandem. 44 Therefore, the selectivity and functionality of lipopeptide-based adjuvants can be improved by rearranging the peptide sequences.
Jackson et al report the use of various modified lipopeptides as anti-tumor immuno-adjuvants. 45, 46 A lipopeptide containing a branched cationic peptide (lysine/arginine) had affinity for negatively charged proteins and showed efficient adjuvant activity. 45 To 
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